Dung-Tsa Chen

Dr. Dung-Tsa Chen

Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDung-Tsa Chen
Dung-Tsa Chen
ADAshley H. Davis-Yadley
Ashley H. Davis-Yadley
PHPo-Yu Huang
Po-Yu Huang
KHKazim Husain
Kazim Husain
BCBarbara A. Centeno
Barbara A. Centeno
MMMokenge Malafa
Mokenge Malafa
The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment decision-making process. To derive a prognostic gene signature for patients with early stage PDAC, a PDAC cohort from Moffitt Cancer Center (n = 63) was used with overall survival (OS) as the primary endpoint. This was further evaluated using an independent microarray cohort dataset (Stratford et al: n = 102). Technical validation was performed by NanoString platform. A prognostic 15-gene signature was developed and showed a statistically significant association with OS in the Moffitt cohort (hazard ratio [HR] = 3.26; p<0.001) and Stratford et al cohort (HR = 2.07; p = 0.02), and was independent of other prognostic variables. Moreover, integration of the signature with the TNM staging system improved risk prediction (p<0.01 in both cohorts). In addition, NanoString validation showed that the signature was robust with a high degree of reproducibility and the association with OS remained significant in the two cohorts. The gene signature could be a potential prognostic tool to allow risk-adapted stratification of PDAC patients into personalized treatment protocols; possibly improving the currently poor clinical outcomes of these patients.

8 December 2011 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
DCDung-Tsa Chen
Dung-Tsa Chen
YHYing-Lin Hsu
Ying-Lin Hsu
WFWilliam J. Fulp
William J. Fulp
DCDomenico Coppola
Domenico Coppola
EHEric B. Haura
Eric B. Haura
WCW. Douglas Cress
W. Douglas Cress
The malignancy-risk gene signature is composed of numerous proliferative genes and has been applied to predict breast cancer risk. We hypothesized that the malignancy-risk gene signature has prognostic and predictive value for early-stage non–small cell lung cancer (NSCLC) patients. The ability of the malignancy-risk gene signature to predict overall survival (OS) of early-stage NSCLC patients was tested using a large NSCLC microarray dataset from the Director’s Challenge Consortium (n = 442) and two independent NSCLC microarray datasets (n = 117 and 133, for the GSE13213 and GSE14814 datasets, respectively). An overall malignancy-risk score was generated by principal component analysis to determine the prognostic and predictive value of the signature. An interaction model was used to investigate a statistically significant interaction between adjuvant chemotherapy (ACT) and the gene signature. All statistical tests were two-sided. The malignancy-risk gene signature was statistically significantly associated with OS (P < .001) of NSCLC patients. Validation with the two independent datasets demonstrated that the malignancy-risk score had prognostic and predictive values: Of patients who did not receive ACT, those with a low malignancy-risk score had increased OS compared with a high malignancy-risk score (P = .007 and .01 for the GSE13212 and GSE14814 datasets, respectively), indicating a prognostic value; and in the GSE14814 dataset, patients receiving ACT survived longer in the high malignancy-risk score group (P = .03), and a statistically significant interaction between ACT and the signature was observed (P = .02). The malignancy-risk gene signature was associated with OS and was a prognostic and predictive indicator. The malignancy-risk gene signature could be useful to improve prediction of OS and to identify those NSCLC patients who will benefit from ACT.

15 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JPJennifer Permuth
Jennifer Permuth
KDKaleena Dezsi
Kaleena Dezsi
SVShraddha Vyas
Shraddha Vyas
KAKarla N. Ali
Karla N. Ali
TBToni L. Basinski
Toni L. Basinski
OCon behalf of the Florida Pancreas Collaborative
on behalf of the Florida Pancreas Collaborative
Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research. However, most biorepositories have poor representation of minority groups, limiting the ability to address health disparities. Methods: We describe the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective cohort study and biorepository designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). We provide an overview of stakeholders; study eligibility and design; recruitment strategies; standard operating procedures to collect, process, store, and transfer biospecimens, medical images, and data; our cloud-based data management platform; and progress regarding recruitment and biobanking. Results: The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and questionnaires (62%). Conclusions: This biorepository addresses a critical gap in PaCa research and has potential to advance translational studies intended to minimize disparities and reduce PaCa-related morbidity and mortality.

7 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DCDung-Tsa Chen
Dung-Tsa Chen
PHPo-Yu Huang
Po-Yu Huang
HLHui-Yi Lin
Hui-Yi Lin
ACAlberto A. Chiappori
Alberto A. Chiappori
DGDmitry I. Gabrilovich
Dmitry I. Gabrilovich
JGJhanelle E. Gray
Jhanelle E. Gray
Purpose: Many phase II clinical trials evaluate unique experimental drugs/combinations through multi-arm design to expedite the screening process (early termination of ineffective drugs) and to identify the most effective drug (pick the winner) to warrant a phase III trial. Various statistical approaches have been developed for the pick-the-winner design but have been criticized for lack of objective comparison among the drug agents.

22 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CFCiara L. Freeman
Ciara L. Freeman
RAReginald Atkins
Reginald Atkins
IVIndumathy Varadarajan
Indumathy Varadarajan
MMMeghan Menges
Meghan Menges
JEJeffrey Edelman
Jeffrey Edelman
FLFrederick L Locke
Frederick L Locke
Purpose: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded with full-length survivin (Ad-S), with mutations neutralizing its antiapoptotic function, could safely generate an immune response and deepen clinical responses when administered before and after autologous stem cell transplant (ASCT) for multiple myeloma. Patients and Methods: This phase I first-in-human trial (NCT02851056) evaluated the safety of DC:Ad-S in newly diagnosed multiple myeloma not having achieved complete response with induction, given 7 to 30 days prior to stem cell collection and 20 to 34 days after ASCT. Anti-survivin antibodies and CD4+ and CD8+ specific T cells were quantified. Results: A total of 14 patients were treated and 13 included in the primary efficacy analysis. No serious adverse events were attributed to DC:Ad-S vaccine. Detectable anti-survivin antibodies increased from baseline in 9 of 13 (69%) patients, and 11 of 13 (85%) mounted either a cellular or humoral immune response to survivin. Seven patients had an improved clinical response at day +90, all of whom had mounted an immune response, and 6 of 7 patients remain event-free at a median follow-up of 4.2 years. Estimated progression-free survival at 4 years is 71% (95% confidence interval, 41–88). Conclusions: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach. See related commentary by Dhodapkar, p. 4524

14 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LCLu Chen
Lu Chen
CKCourtney A. Kurtyka
Courtney A. Kurtyka
EWEric A. Welsh
Eric A. Welsh
JRJason I. Rivera
Jason I. Rivera
BEBrienne E. Engel
Brienne E. Engel
WCW. Douglas Cress
W. Douglas Cress
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma